SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 

 
FORM 8-K
 

 
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
 

 
Date Of Report (Date Of Earliest Event Reported): August 30, 2011
 

 
NORTHWEST BIOTHERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Its Charter)
 

 
Delaware
 
0-33393
 
94-3306718
(State Or Other Jurisdiction Of Incorporation)
 
(Commission File Number)
 
(I.R.S. Employer  Identification No.)
 
4800 Montgomery Lane, Suite 800, Bethesda, MD 20814 

(Address Of Principal Executive Offices) (Zip Code)

Registrant’s Telephone Number, Including Area Code (240) 497-9024

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o  
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o  
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 


 
 

 
 
Item 7.01
Regulation FD Disclosure.
 
On August 30, 2011, the Registrant obtained confirmation of completion of the FDA’s clearance for the Registrant’s Phase I trial with its DCVax® Direct for solid tumor cancers.  DCVax® Direct is a personalized immune therapy for direct injection into tumors.
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
NORTHWEST BIOTHERAPEUTICS, INC
 
       
Dated: September 2, 2011
By:
/s/ Linda Powers
 
   
Linda Powers
 
   
Chief Executive Officer and Chairman